| Document |
Document Title |
|
WO/2011/110614A1 |
Disclosed are compounds of formula (I) wherein n is 1 or 2; and the dotted line together with carbon - carbon bond represents a single bond or a double bond. Furthermore, flavour and fragrance compositions comprising at least one compoun...
|
|
WO/2011/095668A1 |
The present invention relates to the fields of biomedicine and pharmaceutical chemistry, specifically to the use of yessotoxin and analogues and derivatives thereof in the preparation of a medicine for preventing and/or treating neurodeg...
|
|
WO/2011/072623A1 |
Benzomacrolides of formula I which have pancreatic lipase inhibition activity, preparation methods and uses thereof are disclosed, in which R' or R'' is hydrogen, acetyl or propionyl respectively.
|
|
WO/2011/061666A1 |
The present invention provides compounds represented by formula (1): wherein, R1, R2, R3 and R4 are as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceu...
|
|
WO/2011/036299A1 |
The present invention provides new compounds (I) having a kinase inhibitory activity and useful for treating cancer.
|
|
WO/2011/033532A1 |
Disclosed here is a process for preparation of compound 11 - (Z) - [3 - (Dimethylamino) propylidene] - 6, 11 - dihydrodibenz [b, e] oxepin -2 - yl - acetic acid (Olopatadine) and its pharmaceutically acceptable salt comprising reacting c...
|
|
WO/2011/027906A1 |
Provided is a novel compound which is excellent in odor quality, has a natural feeling and a fruity feeling and has a musk aroma. The present invention relates to a compound represented by the following formula (1): [Chem. 1] wherein wav...
|
|
WO/2011/016351A1 |
The purpose of the present invention is to find compounds having a DNA synthase inhibitory effect and provide novel medicinal compositions (DNA synthase inhibitors, anticancer agents and antiinflammatory agents) using said compounds. Dis...
|
|
WO/2011/013651A1 |
Disclosed is a compound represented by general formula (I) (wherein the definition for each group is as described in the description) or a salt, solvate or prodrug thereof, which has a potent and long-lasting ocular hypotensive activity ...
|
|
WO/2010/127928A1 |
The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, n...
|
|
WO/2010/121877A2 |
The present invention relates to a novel process for the preparation of olopatadine hydrochloride starting from an advanced intermediate.
|
|
WO/2010/119274A1 |
A monomer having the general formula (a): in which R1 is any substitution; R2 is any substitution; R1 and R2 may be linked to form a saturated or unsaturated ring; L represents a reactive leaving group; X and Y each independently represe...
|
|
WO/2010/115478A1 |
This invention is directed generally to a process for producing Zeranol that eliminates high pressure and high temperature hydrogenations and provides high selectivity for Zeranol at improved yields.
|
|
WO/2010/089268A2 |
The present invention relates to a process for the preparation of olopatadine and, more particularly, to an improved method of synthesizing olopatadine which comprises reacting a dibenz[b,e]oxepin-1 1-one derivative of formula (III) and ...
|
|
WO/2010/087381A1 |
Disclosed is a process for producing (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz- [b,e]oxepin-2-acetic acid or an acid addition salt thereof, which comprises subjecting 11-hydroxy-11-(3-dimethylaminopropyl)- 6,11-dihydrodibenz...
|
|
WO/2010/082684A1 |
A novel musk-based fragrance having an excellent musky fragrance is provided. Also provided is a fragrance composition containing, as an active ingredient, a macrocyclic lactone compound represented by the following formula (1): wherein ...
|
|
WO/2010/082219A2 |
Malaria is a vector borne infectious disease caused by protozoan parasites. Oil based arteether injections are used as anti-malarial drugs, specifically for the treatment of chloroquine resistant Plasmodium falciparum malaria and cerebra...
|
|
WO/2010/080577A2 |
The present invention relates to new oxepine modulators of H1 receptors and/or inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2010/078396A2 |
The present disclosure provides optionally substituted seven-membered ring isomers of naturally occurring carbohydrate compounds, methods of synthesizing these compounds, intermediate compounds, methods of synthesizing the intermediate c...
|
|
WO/2010/061944A1 |
A 11-hydroxy-11-(3-dimethylaminopropyl)-6,11-dihydrodibenzo[
b,e]oxepine 2-acetic acid ester represented by formula [I] (wherein R1, R2, and R3 each independently represents C1-4 alkyl) or an acid addition salt thereof is heated in a s...
|
|
WO/2010/046194A1 |
Cyclohexanedione compounds, which are suitable for use as herbicides.
|
|
WO/2010/040843A2 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, X and Y are defined as cited in the description. The compounds have an immune-modulating action and inhibit or regulate the release of IL-1β and/or TNF-α. They...
|
|
WO/2010/010934A1 |
Disclosed are: a compound represented by formula (I) [wherein m represents a number of 0 to 2; n represents a number of 1 or 2; p represents a number of 0 to 2; q represents a number of 0 or 1; R1 represents a halogen, a C1-2 alkyl, or t...
|
|
WO/2010/010935A1 |
Disclosed are: a compound represented by formula (I) [wherein m represents a number of 1 or 2; n represents a number of 0 or 1; R1 and R2 independently represent H or a C1-2 alkyl group or may, together with a carbon atom to which both R...
|
|
WO/2010/007056A1 |
Olopatadine can be obtained by means of a process comprising hydrolysis of a compound of general formula (II), wherein Y is OR1, wherein R1 is C1-C7 alkyl, C3-C7 cycloalkyl, aryl, arylalkyl, or heterocycle; or NR2R3, wherein R2 and R3, i...
|
|
WO/2009/134899A2 |
The present invention provides for a non-naturally occurring polyketide synthase (PKS) capable of synthesizing a carboxylic acid or a lactone, and a composition such that a carboxylic acid or lactone is included. The carboxylic acid or l...
|
|
WO/2005/113533A9 |
The invention relates to a process for preparing saturated or unsaturated lactones. This process involves reacting a bicyclic compound or a monocyclic compound with hydrogen peroxide in the presence of a first acid having a pKa of 3 or l...
|
|
WO/2009/105969A1 |
The invention discloses novel epothilone analogues, their pharmaceutical compositions, their use and their preparations, especially discloses the compounds of the following formula, their preparations and their use for preparing therapeu...
|
|
WO/2009/105755A2 |
The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, a...
|
|
WO/2009/103534A2 |
The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I).
|
|
WO/2009/092284A1 |
Benzocycloheptene derivatives, preparing processes and pharmaceutical uses thereof. More particularly, the compounds of formula I or their pharmaceutically acceptable salts or hydrates which have activity of anti-HIV, wherein the definit...
|
|
WO/2009/080504A1 |
The invention relates to a method for producing ε-caprolactone from 6-hydroxycapronic acid ester in the gaseous phase in the presence of active carbon as catalyst and subsequent distillation.
|
|
WO/2009/081417A2 |
Disclosed herein is a process for preparation of compound 11 - (Z) - [3 - (Dimethylamino) propylidene] - 6, 11 - dihydrodibenz [b, e] oxepin -2 - yl - acetic acid (Olopatadine) and its pharmaceutically acceptable salt; comprising reactin...
|
|
WO/2009/075818A1 |
Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV) wherein R1-R12 are as defined herein.
|
|
WO/2009/075823A1 |
Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV), wherein R1-R12 are as defined herein.
|
|
WO/2009/059913A1 |
The object of the present invention is a method for producing ε-caprolactone in a purity greater than 99% by cyclization of 6-hydroxycaproic acid ester in the liquid phase at 150 to 400°C and 1 to 1020 hPa abs., separation and condensa...
|
|
WO/2009/055516A1 |
The present invention is directed to a process, having a reduced environmental impact, for preparing phenylamino substituted quaternary salt compounds that are CCR2 antagonists.
|
|
WO/2009/054298A1 |
Disclosed is a process for producing a crystal of (Z)-11-(3'-dimethylaminopropylidene)-6,11- dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride that is useful as a medicinal agent. Specifically disclosed is a process for producing a cr...
|
|
WO/2009/055519A1 |
The present invention is directed to a process, having a reduced environmental impact, for preparing phenylamino substituted quaternary salt compounds that are CCR2 antagonists.
|
|
WO/2009/054202A1 |
A method of organic-compound reaction and a process for producing an organic compound. By the method and process, high reaction selectivity and a high yield of a target substance can be ensured according to purposes. At least two fluids ...
|
|
WO/2009/048086A1 |
Disclosed is a method for purifying (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz- [b,e]oxepin-2-acetic acid represented by the formula [I] or an acid addition salt thereof, which comprises dissolving (Z)-11-(3-dimethylaminoprop...
|
|
WO/2009/044838A1 |
Disclosed is a method wherein (Z)-11-(3- dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2- acetic acid (general name: olopatadine) or an acid addition salt thereof, which is useful as a pharmaceutical product, is produced by pro...
|
|
WO/2009/039675A1 |
The present invention refers to methyl-substituted double-unsaturated macrocyclic lactones comprising 14 to 17 ring atoms of formula (I) wherein n and m are independently selected from 1, 2, 3 and 4 with the proviso that 3 ≤ n + m ≤ ...
|
|
WO/2009/040817A2 |
Salarines and Tulearins isolated from Fascaplysinopsis sp. sponge and synthetic derivatives thereof are provided.
|
|
WO/2009/024103A2 |
The present invention relates to natural brassinosteroids of general formula (I), wherein R is CH2 or O-CH2 group, R2 is hydrogen or hydroxyl, R3 is hydroxyl, R24 is alkyl or alkenyl, which are selected from the group consisting of methy...
|
|
WO/2009/015368A2 |
The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmace...
|
|
WO/2009/015363A1 |
The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I) wherein R3-R6, R8-R10, R13 and Y are as defined h...
|
|
WO/2009/008405A1 |
A process for producing a trans-dibenzoxenopyrrole compound, characterized by conducting reduction, leaving-group conversion, hydrogenation, and methylation in this order. Thus, a trans-dibenzoxenopyrrole compound can be produced through...
|
|
WO/2008/156816A2 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2008/156817A2 |
Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compound...
|
